Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Diazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 8/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 8/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 8/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 8/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 5/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diazepam SCHEMBL16922183 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL9278054 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL1019217 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL21442 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL3043280 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL11345350 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL6298785 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL6014348 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL17555369 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL4370625 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117877646-A | Wheel-rail material rolling contact fatigue damage prediction method based on different evaluation indexes | 西南交通大学 | 2024-04-12 | — | — | CN | claimed |
| US-20230137543-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | NESTEC S.A. (CH) | 2023-05-04 | — | — | US | claimed |
| CN-110585165-B | Abuse resistant capsules | R·P·谢勒技术有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137645-A1 | HIGHLY PURIFIED (R)-3’-HYDROXYBUTYL (R)-3’-HYDROXYBUTYRATE AND (R)-3-HYDROXYBUTYRATE AND COMBINATIONS WITH THERAPEUTICS | Ketone Catalyst Innovations, LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137673-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12599611-B2 | Methods and compositions for treating seizure disorders in pediatric patients | NEURELIS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3952873-A1 | A CLASS OF SMALL-MOLECULE COMPOUNDS AND THEIR PRODRUGS FOR INTERVENTION WITH CAMK2A, AND THEIR USE IN ACUTE BRAIN INJURIES AND CENTRAL HYPERSOMNIAS | Københavns Universitet (DK) | 2022-02-16 | — | — | EP | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| WO-2022017956-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017960-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017909-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017937-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RETT SYNDROME | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017959-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017955-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017958-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH SHAKEN BABY SYNDROME | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | DRD2, HTR2C, SLC18A2 | GABRA1 209/4885GABRG2 148/4885GABRB3 170/4885 |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | GABRA1 604/4885GABRG2 919/4885GABRB3 660/4885 |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | SLC6A13, SLC6A11, SLC6A1 | GABRA1 151/4885GABRG2 186/4885GABRB3 62/4885 |
| US-12599611-B2 | Methods and compositions for treating seizure disorders in pediatric patients | GABRA6, GABRA2, GABRB1 | GABRA1 6/4885GABRG2 12/4885GABRB3 5/4885 |
| US-20260137645-A1 | HIGHLY PURIFIED (R)-3’-HYDROXYBUTYL (R)-3’-HYDROXYBUTYRATE AND (R)-3-HYDROXYBUTYRATE AND COMBINATIONS WITH THERAPEUTICS | IL1B, HADHB, TNF | GABRA1 1316/4885GABRG2 3429/4885GABRB3 228/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | GABRA1 4274/4885GABRG2 2880/4885GABRB3 3499/4885 |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | FLNB, SETD1B, HTR5A | GABRA1 1638/4885GABRG2 2547/4885GABRB3 701/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GABRA1 1925/4885GABRG2 2584/4885GABRB3 2429/4885 |
| US-20260137673-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | HTT, HTR2C, NSD1 | GABRA1 1362/4885GABRG2 980/4885GABRB3 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.